ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2025
Integration of automated peak frequency annotation with voltage mapping for identifying ventricular tachycardia ablation sites.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Convolutional neural network for real‑time localization of ganglionated plexi from bipolar intracardiac electrograms.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeak frequency (PF) analysis has emerged as a novel tool for identifying arrhythmogenic substrates in ventricular tachycardia (VT) ablation, particularly when combined with traditional substrate mapping techniques such as voltage mapping and Isochronal Late Activation Mapping (ILAM). This study evaluates the utility of PF analysis in scarred myocardial regions, with a focus on areas containing manually annotated late potentials (LPs).
methodsElectroanatomical mapping using the EnSite X™ system was performed in 20 patients undergoing VT ablation. PF analysis was applied to scarred regions with voltages < 1.5 mV, with and without LPs, to identify zones of high-frequency activity. PF zones (PFZs) were compared to voltage maps and ILAM to assess spatial correlation with deceleration zones (DZs) and their role in defining ablation targets.
resultsPeak frequency distributions differed significantly across myocardium conditions (H = 254.92, p < 0.0001). The median peak frequency was 120.0 Hz (77.3-179.0 Hz) in normal voltage myocardium, 145.0 Hz (100.0-194.3 Hz) in low-voltage myocardium without LPs, and 291.0 Hz (190.3-380.3 Hz) in low-voltage myocardium with LPs. Pairwise comparisons showed significant differences: normal voltage vs. low voltage without LPs (U = 46,455.0; p = 0.0019), normal voltage vs. low voltage with LPs (U = 20,935.5; p < 0.0001), and low voltage without LPs vs. low voltage with LPs (U = 19,548.0; p < 0.0001). PFZs exhibited strong colocalization with DZs identified via ILAM, with > 50% spatial overlap in most cases. The automated peak frequency annotation algorithm demonstrated high reproducibility, significantly reducing operator dependency compared to manual annotation.
conclusionPF analysis provides a robust and reproducible method for identifying arrhythmogenic substrates in VT ablation. When integrated with voltage mapping and ILAM, it facilitates precise localization of critical ablation targets, particularly in regions with LPs. These findings highlight the potential of PF analysis to enhance the efficacy of substrate-based ablation strategies.
Indexed as
Identifiers
40237974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.